Synonym
ALN-101; EML-676; IDD-676; IDD-000676-01; IDD-00067601; ALN101; EML676; IDD676; IDD00067601; IDD00067601; ALN 101; EML 676; IDD 676; IDD 000676 01; IDD 00067601
IUPAC/Chemical Name
2-(3-((4,5,7-trifluorobenzo[d]thiazol-2-yl)methyl)-1H-indol-1-yl)acetic acid
InChi Key
KYHVTMFADJNSGS-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25)
SMILES Code
O=C(O)CN1C=C(CC2=NC3=C(F)C(F)=CC(F)=C3S2)C4=C1C=CC=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
376.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Noh HL, Hu Y, Park TS, DiCioccio T, Nichols AJ, Okajima K, Homma S, Goldberg IJ. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther. 2009 Feb;328(2):496-503. doi: 10.1124/jpet.108.136283. PubMed PMID: 18974362; PubMed Central PMCID: PMC2682276.
2: Van Zandt MC, Jones ML, Gunn DE, Geraci LS, Jones JH, Sawicki DR, Sredy J, Jacot JL, Dicioccio AT, Petrova T, Mitschler A, Podjarny AD. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J Med Chem. 2005 May 5;48(9):3141-52. PubMed PMID: 15857120.
3: Soltesova Prnova M, Majekova M, Milackova I, Díez-Dacal B, Pérez-Sala D, Ceyhan MS, Banerjee S, Stefek M. [5-(Benzyloxy)-1H-indol-1-yl]acetic acid, an aldose reductase inhibitor and PPARγ ligand. Acta Biochim Pol. 2015;62(3):523-8. doi: 10.18388/abp.2014_953. PubMed PMID: 26345091.
4: Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. Mini Rev Med Chem. 2016;16(2):120-62. Review. PubMed PMID: 26349493.
5: Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004 Apr;47(4):718-24. PubMed PMID: 15298349.
